JP2024539721A - キナーゼ依存性障害の治療のための化合物 - Google Patents
キナーゼ依存性障害の治療のための化合物 Download PDFInfo
- Publication number
- JP2024539721A JP2024539721A JP2024526617A JP2024526617A JP2024539721A JP 2024539721 A JP2024539721 A JP 2024539721A JP 2024526617 A JP2024526617 A JP 2024526617A JP 2024526617 A JP2024526617 A JP 2024526617A JP 2024539721 A JP2024539721 A JP 2024539721A
- Authority
- JP
- Japan
- Prior art keywords
- ppm
- less
- compound
- formula
- contaminants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275255P | 2021-11-03 | 2021-11-03 | |
| US63/275,255 | 2021-11-03 | ||
| PCT/US2022/048770 WO2023081253A1 (en) | 2021-11-03 | 2022-11-03 | Compounds for the treatment of kinase-dependent disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539721A true JP2024539721A (ja) | 2024-10-29 |
| JP2024539721A5 JP2024539721A5 (https=) | 2025-11-11 |
Family
ID=84462825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526617A Pending JP2024539721A (ja) | 2021-11-03 | 2022-11-03 | キナーゼ依存性障害の治療のための化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250051284A1 (https=) |
| EP (1) | EP4426678A1 (https=) |
| JP (1) | JP2024539721A (https=) |
| CN (1) | CN118176182A (https=) |
| AR (1) | AR127561A1 (https=) |
| AU (1) | AU2022383160A1 (https=) |
| CA (1) | CA3235602A1 (https=) |
| TW (1) | TW202334090A (https=) |
| WO (1) | WO2023081253A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| KR102828472B1 (ko) * | 2018-12-13 | 2025-07-03 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| MX2021014773A (es) * | 2019-06-03 | 2022-01-18 | Exelixis Inc | Formas de sales cristalinas de un inhibidor de cinasas. |
| CN115461328B (zh) * | 2020-04-30 | 2025-11-07 | 埃克塞里艾克西斯公司 | 用于制备激酶抑制剂的方法 |
| JP2023548855A (ja) * | 2020-11-05 | 2023-11-21 | エグゼリクシス， インコーポレイテッド | キナーゼ阻害剤の医薬組成物 |
-
2022
- 2022-11-02 TW TW111141900A patent/TW202334090A/zh unknown
- 2022-11-02 AR ARP220103011A patent/AR127561A1/es unknown
- 2022-11-03 US US18/706,757 patent/US20250051284A1/en active Pending
- 2022-11-03 CN CN202280073218.2A patent/CN118176182A/zh active Pending
- 2022-11-03 CA CA3235602A patent/CA3235602A1/en active Pending
- 2022-11-03 AU AU2022383160A patent/AU2022383160A1/en active Pending
- 2022-11-03 EP EP22821747.7A patent/EP4426678A1/en active Pending
- 2022-11-03 JP JP2024526617A patent/JP2024539721A/ja active Pending
- 2022-11-03 WO PCT/US2022/048770 patent/WO2023081253A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN118176182A (zh) | 2024-06-11 |
| AR127561A1 (es) | 2024-02-07 |
| WO2023081253A1 (en) | 2023-05-11 |
| CA3235602A1 (en) | 2023-05-11 |
| US20250051284A1 (en) | 2025-02-13 |
| AU2022383160A1 (en) | 2024-05-02 |
| EP4426678A1 (en) | 2024-09-11 |
| TW202334090A (zh) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018220045B2 (en) | C-met modulator pharmaceutical compositions | |
| CN106008462A (zh) | 一种alk抑制剂的结晶形式 | |
| TW201524507A (zh) | 雜環化合物及其用途 | |
| CN100406436C (zh) | 阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法 | |
| JP2022504943A (ja) | アミノピリミジン誘導体又はその塩を含む経口投与用医薬組成物 | |
| EP4328226A1 (en) | Tolebrutinib crystal form, amorphous form, preparation method therefor and use thereof | |
| US11820772B2 (en) | Polymorphs of the hydrochloride salt of linaprazan glurate | |
| JP2011500780A (ja) | 新規結晶形 | |
| JP2008539278A (ja) | 結晶性ロスバスタチンカルシウム | |
| TW202308991A (zh) | 三苯化合物之固體形式 | |
| JP2019055960A (ja) | 薬学的に活性な化合物の固体形態 | |
| JP2024539721A (ja) | キナーゼ依存性障害の治療のための化合物 | |
| JP2004504390A (ja) | （ｒ）−ｎ−［５−メチル−８−（４−メチルピペラジン−１−イル）−１，２，３，４−テトラヒドロ−２−ナフチル］−４−モルホリノベンズアミドの新規な形態 | |
| WO2024095127A1 (en) | Solid state forms of tivozanib and process for preparation thereof | |
| WO2022086899A1 (en) | Solid state forms of pralsetinib and process for preparation thereof | |
| EP4073058A1 (en) | Solid state form of lemborexant | |
| WO2022253261A1 (zh) | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 | |
| WO2024201244A1 (en) | Solid state forms of bavdegalutamide and process for preparation thereof | |
| WO2025191534A1 (en) | Solid state forms of zasocitinib and process for preparation thereof | |
| WO2025057087A1 (en) | Solid state forms of samuraciclib | |
| EP4214195A1 (en) | Solid state forms of gefapixant and process for preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251031 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251031 |